NASDAQ:GHDX - Genomic Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$66.46 +1.34 (+2.06 %)
(As of 04/25/2019 04:00 PM ET)
Previous Close$65.12
Today's Range$64.75 - $66.67
52-Week Range$31.16 - $92.18
Volume226,789 shs
Average Volume458,513 shs
Market Capitalization$2.45 billion
P/E Ratio63.30
Dividend YieldN/A
Beta0.95
Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.

Receive GHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GHDX
CUSIP37244C10
Phone650-556-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$394.11 million
Cash Flow$1.4613 per share
Book Value$7.48 per share

Profitability

Net Income$25.68 million

Miscellaneous

Employees829
Market Cap$2.45 billion
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

Genomic Health (NASDAQ:GHDX) Frequently Asked Questions

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) issued its quarterly earnings data on Wednesday, February, 20th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.30 by $0.02. The medical research company earned $104.56 million during the quarter, compared to the consensus estimate of $101.55 million. Genomic Health had a net margin of 6.52% and a return on equity of 16.86%. The firm's revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 earnings per share. View Genomic Health's Earnings History.

When is Genomic Health's next earnings date?

Genomic Health is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Genomic Health.

What guidance has Genomic Health issued on next quarter's earnings?

Genomic Health issued an update on its FY19 earnings guidance on Wednesday, February, 20th. The company provided EPS guidance of $1.38-1.54 for the period, compared to the Thomson Reuters consensus estimate of $1.25. The company issued revenue guidance of $436-448 million, compared to the consensus revenue estimate of $439.74 million.

What price target have analysts set for GHDX?

10 Wall Street analysts have issued twelve-month price targets for Genomic Health's stock. Their forecasts range from $33.00 to $97.00. On average, they anticipate Genomic Health's share price to reach $61.7143 in the next year. This suggests that the stock has a possible downside of 7.1%. View Analyst Price Targets for Genomic Health.

What is the consensus analysts' recommendation for Genomic Health?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 8 hold ratings, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health.

Has Genomic Health been receiving favorable news coverage?

News coverage about GHDX stock has been trending somewhat positive this week, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genomic Health earned a news impact score of 1.5 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.

Are investors shorting Genomic Health?

Genomic Health saw a increase in short interest in March. As of March 15th, there was short interest totalling 2,002,885 shares, an increase of 44.5% from the February 28th total of 1,386,018 shares. Based on an average daily trading volume, of 525,653 shares, the short-interest ratio is presently 3.8 days. Currently, 5.7% of the company's shares are short sold. View Genomic Health's Current Options Chain.

Who are some of Genomic Health's key competitors?

What other stocks do shareholders of Genomic Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genomic Health investors own include NVIDIA (NVDA), Horizon Pharma (HZNP), Revance Therapeutics (RVNC), Illumina (ILMN), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), Intuitive Surgical (ISRG), Exelixis (EXEL), Incyte (INCY) and Vanda Pharmaceuticals (VNDA).

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:
  • Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 60)
  • Dr. Steven Shak, Co-Founder & Chief Scientific Officer (Age 68)
  • Mr. G. Bradley Cole, Chief Financial Officer (Age 63)
  • Dr. Frederic G. Pla, Chief Operating Officer (Age 60)
  • Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 56)

Who are Genomic Health's major shareholders?

Genomic Health's stock is owned by many different of institutional and retail investors. Top institutional investors include Copper Rock Capital Partners LLC (0.90%), Scout Investments Inc. (0.18%), Los Angeles Capital Management & Equity Research Inc. (0.08%), First Quadrant L P CA (0.04%), Strs Ohio (0.03%) and Mercer Global Advisors Inc. ADV (0.02%). Company insiders that own Genomic Health stock include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Which major investors are selling Genomic Health stock?

GHDX stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Los Angeles Capital Management & Equity Research Inc., Scout Investments Inc., Strs Ohio and CAPROCK Group Inc.. Company insiders that have sold Genomic Health company stock in the last year include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, Henry J Fuchs, James J Vaughn, Jason W Radford, Kimberly J Popovits, Laura Leber and Steven Shak. View Insider Buying and Selling for Genomic Health.

Which major investors are buying Genomic Health stock?

GHDX stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Mercer Global Advisors Inc. ADV, Mercer Global Advisors Inc. ADV, Brinker Capital Inc., Oppenheimer Asset Management Inc., Virtu Financial LLC, BNP Paribas Arbitrage SA and First Hawaiian Bank. View Insider Buying and Selling for Genomic Health.

How do I buy shares of Genomic Health?

Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of GHDX stock can currently be purchased for approximately $66.46.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $2.45 billion and generates $394.11 million in revenue each year. The medical research company earns $25.68 million in net income (profit) each year or $1.05 on an earnings per share basis. Genomic Health employs 829 workers across the globe.

What is Genomic Health's official website?

The official website for Genomic Health is http://www.genomichealth.com.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]


MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  335 (Vote Underperform)
Total Votes:  616
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Featured Article: What is the S&P 500 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel